The status and influencing factors of COVID-19 vaccination in patients with COPD.

The status and influencing factors of COVID-19 vaccination in patients with COPD.

Publication date: Jul 23, 2024

In this study, we investigated the status and influencing factors of coronavirus disease 2019 (COVID-19) vaccination in patients with chronic obstructive pulmonary disease (COPD). A questionnaire on COVID-19 vaccination in patients with COPD was developed. The clinical characteristics, COVID-19 vaccination status, other relevant vaccinations, and vaccination status of the patients with COPD were collected anonymously. Logistic regression analysis was used to analyze the factors influencing COVID-19 vaccination in patients with COPD. There were 1898 returned questionnaires, of which 1874 were valid. The proportion of patients who completed the COVID-19 vaccination program was 78. 60%. Factors influencing the COVID-19 vaccination rate were: the age of individuals who were 75-85 years old and > 85 years old, acute exacerbation 3-4 times in the previous year, comorbid cardiovascular and endocrine system diseases, failure to take regular medication for COPD, application of non-invasive ventilation machines, believing that their current health condition has deteriorated, believing that the current COVID-19 vaccine is not safe, medical staff not specifying whether they would recommend vaccination against COVID-19, medical staff not recommending the COVID-19 vaccine, and fear of adverse reactions and aggravation of COPD. Patients with COPD had a high COVID-19 vaccination rate in China, whereas patients with pneumonia, influenza, and herpes zoster had a low vaccination rate. Improving the patients’ understanding of the safety and effectiveness of the vaccine and promoting effective communication between medical staff and patients would help increase the vaccination rate of patients with COPD.

Open Access PDF

Concepts Keywords
China Aged
Coronavirus Aged, 80 and over
Covid COPD
Old COVID-19
Vaccination COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
Female
Humans
Influencing factors
Male
Middle Aged
SARS-CoV-2
Surveys and Questionnaires
Vaccination
Vaccination rate

Semantics

Type Source Name
disease MESH COVID-19
disease VO vaccination
disease MESH COPD
disease MESH endocrine system diseases
disease VO COVID-19 vaccine
drug DRUGBANK Etoperidone
disease MESH pneumonia
disease MESH influenza
disease MESH herpes zoster
disease VO effectiveness
disease VO vaccine
disease VO effective
drug DRUGBANK Coenzyme M
drug DRUGBANK Gold
disease VO volume
disease IDO infectivity
disease VO population
disease VO vaccinated
drug DRUGBANK Methionine
disease IDO acute infection
disease MESH respiratory failure
disease MESH complications
disease IDO country
disease MESH infectious diseases
disease MESH respiratory diseases
disease MESH sleep quality
disease VO monthly
disease IDO history
disease MESH allergy
disease MESH marital status
drug DRUGBANK Oxygen
disease VO injection
disease VO dose
drug DRUGBANK Proline
disease MESH Comorbidity
disease MESH hypertension
disease MESH coronary heart disease
disease MESH heart failure
disease MESH cerebral thrombosis
disease MESH duodenal ulcers
disease MESH liver disease
disease MESH diabetes mellitus
disease MESH osteoporosis
disease MESH chronic kidney disease
disease MESH obstructive sleep apnea
disease MESH infection
disease VO CoronaVac
disease IDO site
disease MESH coronary artery disease
disease VO Gap
disease MESH cardiovascular diseases
drug DRUGBANK Piroxicam
disease MESH secondary infection
disease VO time
disease MESH critically ill
disease VO report
disease MESH Syndrome
disease IDO symptom
disease MESH respiratory tract infections
disease MESH cancer
disease MESH autoimmune diseases
disease MESH breast cancer
pathway KEGG Breast cancer

Original Article

(Visited 2 times, 1 visits today)